MedTrace Logo

Palmitoylethanolamide for Chronic Inflammatory Pain Conditions

NCT06273462 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2024-08-15

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate if a supplement called palmitoylethanolamide (PEA) is effective in reducing the pain in patients with chronic inflammatory pain conditions. The main question the trial aims to answer is if PEA works better at treating a patients pain and improving their function better than a placebo.

Participants will be divided into two equal groups and asked to take either PEA or a placebo for 8 weeks.

Conditions

Interventions

DRUG

Palmitoylethanolamide 600mg twice a day

600mg palmitoylethanolamide twice a day

OTHER

placebo

visually identical placebo capsule

Sponsors & Collaborators

  • Navy Medical Center San Diego

    lead FED

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-05
Primary Completion
2025-08-01
Completion
2025-10-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06273462 on ClinicalTrials.gov